AZD-5305 manufacturers
- AZD5305
-
- $115.00 / 1mg
-
2025-12-09
- CAS:2589531-76-8
- Min. Order:
- Purity: 99.93%
- Supply Ability: 10g
|
| | AZD-5305 Basic information |
| Product Name: | AZD-5305 | | Synonyms: | AZD-5305;2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl-;5-[4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methylpicolinamide;repair,AZD5305,Inhibitor,poly ADP ribose polymerase,DNA,AZD-5305,PARP,inhibit,pathway,synthetic,AZD 5305,lethality;5-(4-((7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide;Saruparib (AZD5305);saruparib;5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide | | CAS: | 2589531-76-8 | | MF: | C22H26N6O2 | | MW: | 406.48 | | EINECS: | | | Product Categories: | api | | Mol File: | 2589531-76-8.mol |  |
| | AZD-5305 Chemical Properties |
| Boiling point | 702.6±60.0 °C(Predicted) | | density | 1.246±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 41.67 mg/mL (102.51 mM; Need ultrasonic) | | pka | 11.26±0.40(Predicted) | | form | Solid | | color | Off-white to light yellow | | InChIKey | WQAVGRAETZEADU-UHFFFAOYSA-N | | SMILES | C1(C(NC)=O)=NC=C(N2CCN(CC3=CC4=C(N=C3)C=C(CC)C(=O)N4)CC2)C=C1 |
| | AZD-5305 Usage And Synthesis |
| Uses | Saruparib (AZD5305) is a potent, orally active and selective PARP inhibitor and trapper with IC50 values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair[1][2]. | | in vivo | Saruparib (AZD5305) (0.01-0.3 mg/kg; p.o.; daily, for 35 d; female Han Wistar rats) demonstrates sustained antitumor activity in BRCAm xenograft and PDX models in vivo[1].
| Animal Model: | Female Han Wistar rats with BRCAm xenograft and PDX models (12-13 weeks of age)[1] | | Dosage: | 0.01, 0.03, 0.1, and 0.3 mg/kg | | Administration: | Oral administration; daily, for 35 days | | Result: | Had antitumor efficacy in a dose-dependent manner. |
| | IC 50 | PARP1: 3 nM (IC50); PARP2: 1400 nM (IC50) | | References | [1] Illuzzi G, et, al. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. DOI:10.1158/1078-0432.CCR-22-0301
[2] Johannes JW, et, al. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. J Med Chem. 2021 Oct 14;64(19):14498-14512. DOI:10.1021/acs.jmedchem.1c01012 |
| | AZD-5305 Preparation Products And Raw materials |
|